{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:25:21Z","timestamp":1792178721646,"version":"4.4.0"},"reference-count":133,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.ejmech.2024.116333","type":"journal-article","created":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T04:22:19Z","timestamp":1711081339000},"page":"116333","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Drug development and potential targets for Cushing's syndrome"],"prefix":"10.1016","volume":"270","author":[{"given":"Wei","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liuyi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangyue","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yucheng","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huidan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2024.116333_bib1","doi-asserted-by":"crossref","first-page":"101382","DOI":"10.1016\/j.beem.2020.101382","article-title":"Cushing's syndrome\u2013Disease monitoring: recurrence, surveillance with biomarkers or imaging studies","volume":"34","author":"Ragnarsson","year":"2020","journal-title":"Best Pract. Res. Clin. Endocrinol. Metabol."},{"key":"10.1016\/j.ejmech.2024.116333_bib2","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.tem.2020.04.004","article-title":"The immune system in Cushing's syndrome","volume":"31","author":"Hasenmajer","year":"2020","journal-title":"Trens Endocrinol Metab"},{"key":"10.1016\/j.ejmech.2024.116333_bib3","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ando.2018.03.011","article-title":"Genomic insights into Cushing syndrome","volume":"79","author":"Assi\u00e9","year":"2018","journal-title":"Ann. Endocrinol."},{"key":"10.1016\/j.ejmech.2024.116333_bib4","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ecl.2018.02.001","article-title":"Diagnosis of Cushing's syndrome in the modern era","volume":"47","author":"Nieman","year":"2018","journal-title":"Endocrinol Metab. Clin. N. Am."},{"key":"10.1016\/j.ejmech.2024.116333_bib5","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ecl.2018.01.006","article-title":"Medical therapy for Cushing's syndrome in the twenty-first century","volume":"47","author":"Tritos","year":"2018","journal-title":"Endocrinol Metab. Clin. N. Am."},{"key":"10.1016\/j.ejmech.2024.116333_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2020.101418","article-title":"Cushing syndrome: old and new genes","volume":"34","author":"Tatsi","year":"2020","journal-title":"Best Pract. Res. Clin. Endocrinol. Metabol."},{"key":"10.1016\/j.ejmech.2024.116333_bib7","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S0140-6736(14)61375-1","article-title":"Cushing's syndrome","volume":"386","author":"Lacroix","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2024.116333_bib8","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ecl.2018.02.005","article-title":"Mortality in patients with endogenous Cushing's syndrome","volume":"47","author":"Javanmard","year":"2018","journal-title":"Endocrinol Metab. Clin. N. Am."},{"key":"10.1016\/j.ejmech.2024.116333_bib9","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.ecl.2019.08.005","article-title":"Hypertension and cardiovascular mortality in patients with cushing syndrome","volume":"48","author":"Nieman","year":"2019","journal-title":"Endocrinol Metab. Clin. N. Am."},{"key":"10.1016\/j.ejmech.2024.116333_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2020.101381","article-title":"Cushing's syndrome: treatment and new therapeutic approaches","volume":"34","author":"Ferriere","year":"2020","journal-title":"Best Pract. Res. Clin. Endocrinol. Metabol."},{"key":"10.1016\/j.ejmech.2024.116333_bib11","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ecl.2018.02.006","article-title":"New molecular targets for treatment of Cushing's disease","volume":"47","author":"Foulkes","year":"2018","journal-title":"Endocrinol Metab. Clin. N. Am."},{"key":"10.1016\/j.ejmech.2024.116333_bib12","doi-asserted-by":"crossref","first-page":"E10","DOI":"10.3171\/foc.2007.23.3.12","article-title":"Medical management of Cushing disease","volume":"23","author":"Gross","year":"2007","journal-title":"Neurosurg. Focus"},{"key":"10.1016\/j.ejmech.2024.116333_bib13","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1590\/S0004-27302007000800020","article-title":"Pharmacological management of Cushing's syndrome: an update","volume":"51","author":"Dang","year":"2007","journal-title":"Arq. Bras. Endocrinol. Metabol."},{"key":"10.1016\/j.ejmech.2024.116333_bib14","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.tibs.2013.05.005","article-title":"Menin: a scaffold protein that controls gene expression and cell signaling","volume":"38","author":"Matkar","year":"2013","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.ejmech.2024.116333_bib15","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ijscr.2017.11.034","article-title":"Case report: ectopic Cushing's syndrome in a young male with hidden lung carcinoid tumor","volume":"42","author":"Aljassem","year":"2018","journal-title":"Int J Surg Case Rep"},{"key":"10.1016\/j.ejmech.2024.116333_bib16","first-page":"4","article-title":"Exogenous Cushing's syndrome secondary to intermittent high dose oral prednisone for presumed asthma exacerbations in the setting of multiple emergency department visits","volume":"6","author":"Sanjay","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejmech.2024.116333_bib17","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.mpmed.2017.05.007","article-title":"Cushing's syndrome","volume":"45","author":"Eleni","year":"2017","journal-title":"Medicine"},{"key":"10.1016\/j.ejmech.2024.116333_bib18","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S2213-8587(19)30343-2","article-title":"Cushing's disease-from Minnie G to key issues in the early 21st century","volume":"7","author":"Kelsall","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.ejmech.2024.116333_bib19","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.tvjl.2018.09.014","article-title":"Treating canine Cushing's syndrome: current options and future prospects","volume":"241","author":"Sanders","year":"2018","journal-title":"Vet. J."},{"key":"10.1016\/j.ejmech.2024.116333_bib20","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/S2213-8587(18)30155-4","article-title":"Advances in the medical treatment of Cushing's syndrome","volume":"7","author":"Feelders","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.ejmech.2024.116333_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.psyneuen.2020.104775","article-title":"Associations between brain activity and endogenous and exogenous cortisol - a systematic review","volume":"120","author":"Harrewijn","year":"2020","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.ejmech.2024.116333_bib22","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ygcen.2009.06.003","article-title":"Inhibition of cortisol metabolism by 17alpha,20beta-P: mechanism mediating semelparity in salmon?","volume":"165","author":"Barry","year":"2010","journal-title":"Gen. Comp. Endocrinol."},{"key":"10.1016\/j.ejmech.2024.116333_bib23","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0022-3956(02)00059-6","article-title":"HPA hyperactivity with increased plasma cortisol affects dexamethasone metabolism and DST outcome","volume":"36","author":"Stokes","year":"2002","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.ejmech.2024.116333_bib24","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.psyneuen.2019.03.001","article-title":"Dehydroepiandrosterone and cortisol as markers of HPA axis dysregulation in women with low sexual desire","volume":"104","author":"Basson","year":"2019","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.ejmech.2024.116333_bib25","doi-asserted-by":"crossref","first-page":"907","DOI":"10.4158\/EP-2018-0111","article-title":"Pathogenesis of cushing disease: an update on the genetics of corticotropinomas","volume":"24","author":"Albani","year":"2018","journal-title":"Endocr. Pract."},{"key":"10.1016\/j.ejmech.2024.116333_bib26","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1210\/edrv-3-3-299","article-title":"The role of lipoproteins in steroidogenesis and cholesterol metabolism in steroidogenic glands","volume":"3","author":"Gwynne","year":"1982","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.ejmech.2024.116333_bib27","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.mce.2006.12.001","article-title":"Adrenal cholesterol utilization","volume":"265\u2013266","author":"Kraemer","year":"2007","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.ejmech.2024.116333_bib28","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0021-9258(18)64914-2","article-title":"Studies on the mechanism of action of the adrenocorticotropic hormone","volume":"225","author":"Haynes","year":"1957","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2024.116333_bib29","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/0022-4731(86)90299-2","article-title":"Transduction of acth signal from plasma membrane to mitochondria in adrenocortical steroidogenesis. Effects of peptide, phospholipid, and calcium","volume":"25","author":"Kimura","year":"1986","journal-title":"J. Steroid Biochem."},{"key":"10.1016\/j.ejmech.2024.116333_bib30","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1210\/er.2010-0013","article-title":"The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders","volume":"32","author":"Miller","year":"2011","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.ejmech.2024.116333_bib31","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.nec.2012.06.012","article-title":"Medical management of persistent and recurrent cushing disease","volume":"23","author":"Fleseriu","year":"2012","journal-title":"Neurosurg. Clin."},{"key":"10.1016\/j.ejmech.2024.116333_bib32","series-title":"Pituitary Tumors","first-page":"231","article-title":"Chapter 16 - medical management of Cushing's disease","author":"Kelsall","year":"2021"},{"key":"10.1016\/j.ejmech.2024.116333_bib33","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1021\/jm021093t","article-title":"A novel somatostatin mimic with broad somatotropin release inhibitory factor receptor binding and superior therapeutic potential","volume":"46","author":"Lewis","year":"2003","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116333_bib34","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1006\/frne.1999.0183","article-title":"Somatostatin and its receptor family","volume":"20","author":"Patel","year":"1999","journal-title":"Front. Neuroendocrinol."},{"key":"10.1016\/j.ejmech.2024.116333_bib35","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.yfrne.2013.07.005","article-title":"Somatostatin receptors: from signaling to clinical practice","volume":"34","author":"Theodoropoulou","year":"2013","journal-title":"Front. Neuroendocrinol."},{"key":"10.1016\/j.ejmech.2024.116333_bib36","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1038\/npp.2016.281","article-title":"Roles of hippocampal somatostatin receptor subtypes in stress response and emotionality","volume":"42","author":"Pr\u00e9v\u00f4t","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejmech.2024.116333_bib37","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1530\/JOE-16-0332","article-title":"Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro","volume":"231","author":"Ib\u00e1\u00f1ez-Costa","year":"2016","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.ejmech.2024.116333_bib38","doi-asserted-by":"crossref","first-page":"E278","DOI":"10.1152\/ajpendo.00004.2005","article-title":"Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells","volume":"289","author":"van der Hoek","year":"2005","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.ejmech.2024.116333_bib39","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1210\/jc.2013-1771","article-title":"Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers","volume":"98","author":"Henry","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejmech.2024.116333_bib40","doi-asserted-by":"crossref","first-page":"6643","DOI":"10.1021\/jm050376t","article-title":"Discovery of iodinated somatostatin analogues selective for hsst2 and hsst5 with excellent inhibition of growth hormone and prolactin release from rat pituitary cells","volume":"48","author":"Moore","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116333_bib41","doi-asserted-by":"crossref","first-page":"4487","DOI":"10.1021\/jm060363v","article-title":"Novel sst2-selective somatostatin agonists. Three-dimensional consensus structure by NMR","volume":"49","author":"Grace","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116333_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2019.105908","article-title":"The modulatory role of dopamine receptors in brain neuroinflammation","volume":"76","author":"Xia","year":"2019","journal-title":"Int. Immunopharm."},{"key":"10.1016\/j.ejmech.2024.116333_bib43","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1210\/jc.2003-030837","article-title":"Dopamine receptor expression and function in corticotroph pituitary tumors","volume":"89","author":"Pivonello","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejmech.2024.116333_bib44","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1210\/jc.2003-030859","article-title":"Dopamine receptor expression and function in clinically nonfunctioning pituitary tumors: Comparison with the effectiveness of cabergoline treatment","volume":"89","author":"Pivonello","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejmech.2024.116333_bib45","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1210\/jc.2008-1533","article-title":"The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery","volume":"94","author":"Pivonello","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejmech.2024.116333_bib46","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa062222","article-title":"Dopamine agonists and the risk of cardiac-valve regurgitation","volume":"356","author":"Schade","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2024.116333_bib47","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMoa054830","article-title":"Valvular heart disease and the use of dopamine agonists for Parkinson's disease","volume":"356","author":"Zanettini","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2024.116333_bib48","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.clinthera.2006.08.004","article-title":"A review of the receptor-binding and pharmacokinetic properties of dopamine agonists","volume":"28","author":"Kvernmo","year":"2006","journal-title":"Clin. Therapeut."},{"key":"10.1016\/j.ejmech.2024.116333_bib49","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1021\/ml3003814","article-title":"Synthesis of novel analogs of cabergoline: improving cardiovascular safety by removing 5-HT2B receptor agonism","volume":"4","author":"Dosa","year":"2013","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2024.116333_bib50","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.mce.2010.07.015","article-title":"Melanocortin receptors and their accessory proteins","volume":"331","author":"Cooray","year":"2011","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.ejmech.2024.116333_bib51","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/j.1749-6632.1993.tb19694.x","article-title":"Cloning and functional characterization of a family of receptors for the melanotropic peptides","volume":"680","author":"Cone","year":"1993","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.ejmech.2024.116333_bib52","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.mehy.2009.10.034","article-title":"ACTH receptor blockade: a novel approach to treat congenital adrenal hyperplasia, or Cushing's disease","volume":"74","author":"Newfield","year":"2010","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.ejmech.2024.116333_bib53","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.mce.2014.07.003","article-title":"Development of potent selective competitive-antagonists of the melanocortin type 2 receptor","volume":"394","author":"Bouw","year":"2014","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.ejmech.2024.116333_bib54","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvaa046.690","article-title":"Mon-176 discovery and identification of late stage selective nonpeptide ACTH antagonists for the treatment of Cushing's disease, ectopic ACTH secreting tumors, and congenital adrenal hyperplasia","volume":"4","author":"Kusnetzow","year":"2020","journal-title":"Journal of the Endocrine Society"},{"key":"10.1016\/j.ejmech.2024.116333_bib55","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvaa046.699","article-title":"OR19-03 effects of nonpeptide orally bioavailable ACTH antagonists on adrenal gland size and function in rats","volume":"4","author":"Markison","year":"2020","journal-title":"Journal of the Endocrine Society"},{"key":"10.1016\/j.ejmech.2024.116333_bib56","doi-asserted-by":"crossref","first-page":"SAT","DOI":"10.1210\/js.2019-SAT-364","article-title":"SAT-364 nonpeptide orally-bioavailable ACTH antagonists: suppression of ACTH-induced corticosterone secretion and adrenal hypertrophy in rats","volume":"3","author":"Kusnetzow","year":"2019","journal-title":"Journal of the Endocrine Society"},{"key":"10.1016\/j.ejmech.2024.116333_bib57","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1210\/jc.2012-2328","article-title":"Potential role for retinoic acid in patients with Cushing's disease","volume":"97","author":"Pecori Giraldi","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejmech.2024.116333_bib58","article-title":"The role of isotretinoin therapy for Cushing's disease: results of a prospective study","volume":"2016","author":"Vilar","year":"2016","journal-title":"Internet J. Endocrinol."},{"key":"10.1016\/j.ejmech.2024.116333_bib59","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1152\/physrev.2001.81.3.1269","article-title":"Nuclear hormone receptors and gene expression","volume":"81","author":"Aranda","year":"2001","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ejmech.2024.116333_bib60","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0303-7207(02)00280-0","article-title":"Glucocorticoid receptors and Cushing's disease","volume":"197","author":"Lamberts","year":"2002","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.ejmech.2024.116333_bib61","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/cen.12728","article-title":"Glucocorticoid receptor function in health and disease","volume":"83","author":"Caratti","year":"2015","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.ejmech.2024.116333_bib62","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/0922-4106(93)90072-H","article-title":"Pharmacological and functional characterization of human mineralocorticoid and glucocorticoid receptor ligands","volume":"247","author":"Rupprecht","year":"1993","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2024.116333_bib63","doi-asserted-by":"crossref","DOI":"10.1097\/01.mnh.0000133976.32559.b0","article-title":"Glucocorticoid-mediated mineralocorticoid receptor activation and hypertension","volume":"13","author":"Frey","year":"2004","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"10.1016\/j.ejmech.2024.116333_bib64","series-title":"Advances in Drug Research","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0065-2490(97)80015-9","article-title":"Development of estrogen antagonists as pharmaceutical agents","author":"Ray","year":"1997"},{"key":"10.1016\/j.ejmech.2024.116333_bib65","series-title":"xPharm: the Comprehensive Pharmacology Reference","first-page":"1","article-title":"Aminoglutethimide","author":"Furman","year":"2007"},{"key":"10.1016\/j.ejmech.2024.116333_bib66","series-title":"xPharm: the Comprehensive Pharmacology Reference","first-page":"1","article-title":"Trilostane","author":"Furman","year":"2007"},{"key":"10.1016\/j.ejmech.2024.116333_bib67","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1080\/09513590601005946","article-title":"Clinical applications of mifepristone","volume":"22","author":"Tang","year":"2006","journal-title":"Gynecol. Endocrinol."},{"key":"10.1016\/j.ejmech.2024.116333_bib68","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1530\/EJE-07-0458","article-title":"Mifepristone (RU 486) in Cushing's syndrome","volume":"157","author":"Johanssen","year":"2007","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.ejmech.2024.116333_bib69","doi-asserted-by":"crossref","first-page":"22748","DOI":"10.1074\/jbc.M212711200","article-title":"The three-dimensional structures of antagonistic and agonistic forms of the glucocorticoid receptor ligand-binding domain: RU-486 induces a transconformation that leads to active antagonism","volume":"278","author":"Kauppi","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2024.116333_bib70","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1021\/jm049266x","article-title":"6,19-Sulfur-Bridged progesterone analogues with antiimmunosuppressive activity","volume":"48","author":"Veleiro","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116333_bib71","doi-asserted-by":"crossref","first-page":"7767","DOI":"10.1021\/acs.jmedchem.8b00743","article-title":"Discovery of a potent and selective steroidal glucocorticoid receptor antagonist (ORIC-101)","volume":"61","author":"Rew","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116333_bib72","doi-asserted-by":"crossref","first-page":"6751","DOI":"10.1021\/acs.jmedchem.9b00711","article-title":"Discovery of a potent steroidal glucocorticoid receptor antagonist with enhanced selectivity against the progesterone and androgen receptors (OP-3633)","volume":"62","author":"Du","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116333_bib73","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/0022-4731(88)90002-7","article-title":"The mechanism of action of steroid antagonists: insights from crystallographic studies","volume":"31","author":"Duax","year":"1988","journal-title":"J. Steroid Biochem."},{"key":"10.1016\/j.ejmech.2024.116333_bib74","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1124\/mol.52.4.749","article-title":"21-Hydroxy-6,19-oxidoprogesterone: a novel synthetic steroid with specific antiglucocorticoid properties in the rat","volume":"52","author":"Vicent","year":"1997","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejmech.2024.116333_bib75","doi-asserted-by":"crossref","first-page":"5704","DOI":"10.1016\/j.bmcl.2007.07.055","article-title":"2-Benzenesulfonyl-8a-benzyl-hexahydro-2H-isoquinolin-6-ones as selective glucocorticoid receptor antagonists","volume":"17","author":"Clark","year":"2007","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2024.116333_bib76","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.bmcl.2008.01.027","article-title":"1H-Pyrazolo[3,4-g]hexahydro-isoquinolines as selective glucocorticoid receptor antagonists with high functional activity","volume":"18","author":"Clark","year":"2008","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2024.116333_bib77","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1016\/j.bmcl.2015.10.097","article-title":"1H-Pyrazolo[3,4-g]hexahydro-isoquinolines as potent GR antagonists with reduced hERG inhibition and an improved pharmacokinetic profile","volume":"25","author":"Hunt","year":"2015","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2024.116333_bib78","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.662865","article-title":"Relacorilant, a selective glucocorticoid receptor modulator, induces clinical improvements in patients with cushing syndrome: results from A prospective, open-label phase 2 study","volume":"12","author":"Pivonello","year":"2021","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.ejmech.2024.116333_bib79","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvac150.1137","article-title":"PMON165 favorable liver safety profile of the selective glucocorticoid receptor modulator relacorilant in healthy and hepatically impaired adults and in patients with cushing syndrome","volume":"6","author":"Moraitis","year":"2022","journal-title":"Journal of the Endocrine Society"},{"key":"10.1016\/j.ejmech.2024.116333_bib80","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.21037\/jgo-22-376","article-title":"Abiraterone acetate for treatment of ectopic Cushing syndrome caused by ACTH-producing neuroendocrine tumor: a case report","volume":"13","author":"Chacko","year":"2022","journal-title":"J. Gastrointest. Oncol."},{"key":"10.1016\/j.ejmech.2024.116333_bib81","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1365-2265.1991.tb03517.x","article-title":"Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome","volume":"35","author":"Verhelst","year":"1991","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.ejmech.2024.116333_bib82","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/ALN.0b013e3181cf40ed","article-title":"Carboetomidate: a pyrrole analog of etomidate designed not to suppress adrenocortical function","volume":"112","author":"Cotten","year":"2010","journal-title":"Anesthesiology"},{"key":"10.1016\/j.ejmech.2024.116333_bib83","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1124\/jpet.117.245332","article-title":"Dimethoxy-etomidate: a nonhypnotic etomidate analog that potently inhibits steroidogenesis","volume":"364","author":"McGrath","year":"2018","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2024.116333_bib84","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1213\/ANE.0b013e31828b3637","article-title":"Carboetomidate: an analog of etomidate that interacts weakly with 11\u03b2-hydroxylase","volume":"116","author":"Shanmugasundararaj","year":"2013","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.ejmech.2024.116333_bib85","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1021\/ml100071j","article-title":"First selective CYP11B1 inhibitors for the treatment of cortisol-dependent diseases","volume":"2","author":"Hille","year":"2011","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2024.116333_bib86","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1021\/ml100283h","article-title":"Optimization of the first selective steroid-11\u03b2-hydroxylase (CYP11B1) inhibitors for the treatment of cortisol dependent diseases","volume":"2","author":"Hille","year":"2011","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2024.116333_bib87","doi-asserted-by":"crossref","first-page":"6022","DOI":"10.1021\/jm400240r","article-title":"Cushing's syndrome: development of highly potent and selective CYP11B1 inhibitors of the (Pyridylmethyl)pyridine type","volume":"56","author":"Emmerich","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116333_bib88","doi-asserted-by":"crossref","first-page":"5086","DOI":"10.1021\/acs.jmedchem.7b00437","article-title":"Lead optimization generates CYP11B1 inhibitors of pyridylmethyl isoxazole type with improved pharmacological profile for the treatment of Cushing's disease","volume":"60","author":"Emmerich","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116333_bib89","doi-asserted-by":"crossref","first-page":"7080","DOI":"10.1021\/jm3004637","article-title":"Selective dual inhibitors of CYP19 and CYP11B2: targeting cardiovascular diseases hiding in the shadow of breast cancer","volume":"55","author":"Hu","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116333_bib90","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejmech.2015.04.013","article-title":"Identification of 4-(4-nitro-2-phenethoxyphenyl)pyridine as a promising new lead for discovering inhibitors of both human and rat 11\u03b2-Hydroxylase","volume":"96","author":"Hu","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116333_bib91","doi-asserted-by":"crossref","first-page":"6629","DOI":"10.1021\/jm3003872","article-title":"Novel imidazole-1-ylmethyl substituted 1,2,5,6-Tetrahydropyrrolo[3,2,1-ij]quinolin-4-ones as potent and selective CYP11B1 inhibitors for the treatment of Cushing's syndrome","volume":"55","author":"Yin","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116333_bib92","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1021\/ml400324c","article-title":"Discovery and in vivo evaluation of potent dual CYP11B2 (aldosterone synthase) and CYP11B1 inhibitors","volume":"4","author":"Meredith","year":"2013","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2024.116333_bib93","doi-asserted-by":"crossref","first-page":"4749","DOI":"10.1021\/acs.jmedchem.5b00407","article-title":"Structure\u2013activity relationships, pharmacokinetics, and in vivo activity of CYP11B2 and CYP11B1 inhibitors","volume":"58","author":"Papillon","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116333_bib94","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1021\/acs.jmedchem.5b01609","article-title":"Exploiting the chromone scaffold for the development of inhibitors of corticosteroid biosynthesis","volume":"59","author":"Gobbi","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116333_bib95","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ejmech.2017.07.078","article-title":"Drifting of heme-coordinating group in imidazolylmethylxanthones leading to improved selective inhibition of CYP11B1","volume":"139","author":"Gobbi","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116333_bib96","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1002\/cmdc.201600078","article-title":"Steroidogenic cytochromes P450 (CYPs) with 6-substituted 1-imidazolylmethylxanthones","volume":"11","author":"Gobbi","year":"2016","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2024.116333_bib97","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0039-128X(96)00033-5","article-title":"11\u03b2-Hydroxysteroid dehydrogenases: key enzymes in determining tissue-specific glucocorticoid effects","volume":"61","author":"Edwards","year":"1996","journal-title":"Steroids"},{"key":"10.1016\/j.ejmech.2024.116333_bib98","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/S1043-2760(03)00134-6","article-title":"11\u03b2-Hydroxysteroid dehydrogenase: unexpected connections","volume":"14","author":"Walker","year":"2003","journal-title":"Trends Endocrinol. Metabol."},{"key":"10.1016\/j.ejmech.2024.116333_bib99","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2337\/diabetes.53.4.931","article-title":"Novel adipose tissue\u2013mediated resistance to diet-induced visceral obesity in 11\u03b2-Hydroxysteroid dehydrogenase type 1\u2013deficient mice","volume":"53","author":"Nicholas","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.ejmech.2024.116333_bib100","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1210\/en.2013-1362","article-title":"11-Dehydrocorticosterone causes metabolic syndrome, which is prevented when 11\u03b2-HSD1 is knocked out in livers of male mice","volume":"154","author":"Harno","year":"2013","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejmech.2024.116333_bib101","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1530\/eje.1.02228","article-title":"Adipose tissue 11\u03b2-hydroxysteroid dehydrogenase type 1 expression in obesity and Cushing's syndrome","volume":"155","author":"Mariniello","year":"2006","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.ejmech.2024.116333_bib102","doi-asserted-by":"crossref","first-page":"5951","DOI":"10.1021\/jm300592r","article-title":"Discovery of a potent, selective, and orally bioavailable acidic 11\u03b2-hydroxysteroid dehydrogenase type 1 (11\u03b2-HSD1) inhibitor: discovery of 2-[(3S)-1-[5-(Cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl]-3-piperidyl]acetic acid (AZD4017)","volume":"55","author":"Scott","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116333_bib103","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1016\/j.bmcl.2015.06.099","article-title":"Discovery of 11\u03b2-hydroxysteroid dehydrogenase type 1 inhibitor","volume":"25","author":"Hong","year":"2015","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2024.116333_bib104","doi-asserted-by":"crossref","first-page":"5268","DOI":"10.1158\/1078-0432.CCR-05-1554","article-title":"The epidermal growth factor receptor pathway: a model for targeted therapy","volume":"12","author":"Scaltriti","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2024.116333_bib105","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2022.101701","article-title":"Innovative tumour targeting therapeutics in Cushing's disease","volume":"36","author":"von Selzam","year":"2022","journal-title":"Best Pract. Res. Clin. Endocrinol. Metabol."},{"key":"10.1016\/j.ejmech.2024.116333_bib106","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.1172\/JCI60417","article-title":"EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas","volume":"121","author":"Fukuoka","year":"2011","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejmech.2024.116333_bib107","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/cr.2015.20","article-title":"Recurrent gain-of-function USP8 mutations in Cushing's disease","volume":"25","author":"Ma","year":"2015","journal-title":"Cell Res."},{"key":"10.1016\/j.ejmech.2024.116333_bib108","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1093\/emboj\/17.12.3241","article-title":"UBPY: a growth-regulated human ubiquitin isopeptidase","volume":"17","author":"Naviglio","year":"1998","journal-title":"EMBO J."},{"key":"10.1016\/j.ejmech.2024.116333_bib109","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/ng.3166","article-title":"Mutations in the deubiquitinase gene USP8 cause Cushing's disease","volume":"47","author":"Reincke","year":"2015","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ejmech.2024.116333_bib110","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15020496","article-title":"Advances in molecular pathophysiology and targeted therapy for Cushing's disease","volume":"15","author":"Takayasu","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2024.116333_bib111","doi-asserted-by":"crossref","first-page":"785","DOI":"10.3389\/fendo.2019.00785","article-title":"Expression of EGFR in pituitary corticotroph adenomas and its relationship with tumor behavior","volume":"10","author":"Liu","year":"2019","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.ejmech.2024.116333_bib112","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1038\/s42003-021-02802-x","article-title":"Molecular basis of ubiquitin-specific protease 8 autoinhibition by the WW-like domain","volume":"4","author":"Kakihara","year":"2021","journal-title":"Commun. Biol."},{"key":"10.1016\/j.ejmech.2024.116333_bib113","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/cmdc.200900409","article-title":"Synthesis and biological evaluation of 9-oxo-9H-indeno[1,2-b]pyrazine-2,3-dicarbonitrile analogues as potential inhibitors of deubiquitinating enzymes","volume":"5","author":"Colombo","year":"2010","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2024.116333_bib114","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1507\/endocrj.EJ19-0239","article-title":"Ubiquitin-specific protease 8 inhibitor suppresses adrenocorticotropic hormone production and corticotroph tumor cell proliferation","volume":"67","author":"Kageyama","year":"2020","journal-title":"Endocr. J."},{"key":"10.1016\/j.ejmech.2024.116333_bib115","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1038\/s41467-018-05275-5","article-title":"Identification of recurrent USP48 and BRAF mutations in Cushing's disease","volume":"9","author":"Chen","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2024.116333_bib116","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/nm.3776","article-title":"A C-terminal HSP90 inhibitor restores glucocorticoid sensitivity and relieves a mouse allograft model of Cushing disease","volume":"21","author":"Riebold","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2024.116333_bib117","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/j.cell.2014.04.038","article-title":"Glucocorticoid receptor function regulated by coordinated action of the Hsp90 and Hsp70 chaperone cycles","volume":"157","author":"Kirschke","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2024.116333_bib118","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.cell.2005.11.026","article-title":"The many faces of PPAR\u03b3","volume":"123","author":"Lehrke","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2024.116333_bib119","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1038\/nm784","article-title":"Functional PPAR-\u03b3 receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas","volume":"8","author":"Heaney","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2024.116333_bib120","doi-asserted-by":"crossref","DOI":"10.1098\/rsob.180112","article-title":"Structural insights into the functional diversity of the CDK-cyclin family","volume":"8","author":"Wood","year":"2018","journal-title":"Open Biol"},{"key":"10.1016\/j.ejmech.2024.116333_bib121","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jbiotec.2015.02.032","article-title":"Discovery and development of Seliciclib. How systems biology approaches can lead to better drug performance","volume":"202","author":"Khalil","year":"2015","journal-title":"J. Biotechnol."},{"key":"10.1016\/j.ejmech.2024.116333_bib122","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1210\/clinem\/dgac588","article-title":"Treatment of cushing disease with pituitary-targeting seliciclib","volume":"108","author":"Liu","year":"2023","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejmech.2024.116333_bib123","doi-asserted-by":"crossref","first-page":"8414","DOI":"10.1073\/pnas.1018091108","article-title":"Targeting zebrafish and murine pituitary corticotroph tumors with a cyclin-dependent kinase (CDK) inhibitor","volume":"108","author":"Liu","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2024.116333_bib124","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1210\/jc.2015-1606","article-title":"Cyclin E-mediated human proopiomelanocortin regulation as a therapeutic target for cushing disease","volume":"100","author":"Liu","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejmech.2024.116333_bib125","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1042\/BCJ20210139","article-title":"Inhibitory feedback control of NF-\u03baB signalling in health and disease","volume":"478","author":"Prescott","year":"2021","journal-title":"Biochem. J."},{"key":"10.1016\/j.ejmech.2024.116333_bib126","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/mco2.104","article-title":"NF-\u03baB signaling in inflammation and cancer","volume":"2","author":"Zhang","year":"2021","journal-title":"MedComm"},{"key":"10.1016\/j.ejmech.2024.116333_bib127","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1021\/jm801344j","article-title":"Phenanthrene-based tylophorine-1 (PBT-1) inhibits lung cancer cell growth through the akt and NF-\u03baB pathways","volume":"52","author":"Lin","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116333_bib128","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/38a101d6-a1f2-4a74-ab63-bc5c61e5f62b","article-title":"Growth suppression of mouse pituitary corticotroph tumor AtT20 cells by curcumin: a model for treating Cushing's disease","volume":"5","author":"Bangaru","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2024.116333_bib129","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.biopha.2017.08.127","article-title":"Triptolide suppresses growth and hormone secretion in murine pituitary corticotroph tumor cells via NF-kappaB signaling pathway","volume":"95","author":"Li","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejmech.2024.116333_bib130","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1530\/JOE-13-0210","article-title":"Mitotane reduces human and mouse ACTH-secreting pituitary cell viability and function","volume":"218","author":"Gentilin","year":"2013","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.ejmech.2024.116333_bib131","doi-asserted-by":"crossref","DOI":"10.1038\/nrendo.2012.141","article-title":"Mitotane\u2014safe and effective for Cushing disease?","volume":"8","author":"Ozerlat","year":"2012","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.ejmech.2024.116333_bib132","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/S2213-8587(21)00235-7","article-title":"Consensus on diagnosis and management of Cushing's disease: a guideline update","volume":"9","author":"Fleseriu","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.ejmech.2024.116333_bib133","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ecl.2020.05.003","article-title":"Advances in the medical treatment of cushing disease","volume":"49","author":"Tritos","year":"2020","journal-title":"Endocrinol Metab. Clin. N. Am."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424002137?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424002137?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T07:10:28Z","timestamp":1738393828000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523424002137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":133,"alternative-id":["S0223523424002137"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.116333","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug development and potential targets for Cushing's syndrome","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.116333","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116333"}}